NHLBI SMARTT Program Awards AlphaCore Pharma Funding to Manufacture Potential Treatment for Familial Lecithin-Cholesterol Acyltransferase (LCAT) Deficiency

ANN ARBOR, Mich. & ROCKVILLE, Md.--(BUSINESS WIRE)--AlphaCore Pharma is awarded NHLBI SMARTT funding to manufacture rhLCAT. ABL to produce rhLCAT under cGMP as the designated biologics production facility under the SMARTT program.

Feed Date: 
February 14, 2012